Evaluation of Pain Management Efficacy Using Injectable Etoricoxib: Findings from the RAPID Study
By
Shiva Shankar Jha
Anoop Dhamangaonkar
Rajkumar Iyengar
Gautam Chakraverty
Kotini Saskar Rao
Abhijeet Mukherji
Sameer Muchhala
Vidhya Natarajan
August 22, 2026
Clinical Scorecard: Evaluation of Pain Management Efficacy Using Injectable Etoricoxib: Findings from the RAPID Study
At a Glance
Category Detail
Condition Acute Pain Management Key Mechanisms Etoricoxib is a selective COX-2 inhibitor providing analgesic and antiinflammatory effects with improved gastrointestinal safety. Target Population Hospitalized patients experiencing acute pain in India. Care Setting Tertiary care hospitals and outpatient clinics.
Key Highlights
Intramuscular etoricoxib 90 mg reduced pain within 60 minutes. Pain relief persisted for up to 24 hours post-injection. Etoricoxib was generally well tolerated with few reported side effects. Injectable etoricoxib addresses the need for rapid analgesia when oral medications are impractical. Study conducted across 68 sites in India. Guideline-Based Recommendations
Diagnosis
Assess pain intensity using the Numeric Pain Rating Scale (NPRS). Management
Administer intramuscular etoricoxib 90 mg for acute pain management when oral intake is impractical. Monitoring & Follow-up
Evaluate pain relief and tolerability based on reported adverse events. Risks
Monitor for potential gastrointestinal toxicity and bleeding risk associated with NSAIDs. Patient & Prescribing Data
Adult patients experiencing acute painful conditions.
Intramuscular etoricoxib provides timely pain control and supports early mobilization.
Clinical Best Practices
Utilize structured acute pain services to improve pain management outcomes. Consider injectable analgesics in patients with contraindications to oral medications. Related Resources & Content
